Sign Up
Stories
FDA Approval Boosts Kamada's Growth
Share
FDA Approval for Kamada's Cytogam Produc...
Immunoglobulin Market Growth and Innovat...
Plasma Innovations and Human Generosity
ANJESO Drug Insight and Market Forecast
Advancements in Cancer Treatment and Mar...
Biosimilar Interleukins Market Growth
Overview
API
Kamada receives US FDA approval to manufacture Cytogam in Israel, completing the technology transfer process from CSL Behring, with plans to start commercial production soon. The approval is significant for Kamada, marking the third product approved for manufacturing at their Israeli site and expecting growth from their FDA-approved IgG portfolio.
Ask a question
How might the FDA approval impact Kamada's market position and competitiveness in the pharmaceutical industry?
In what ways could Nanogam 5% revolutionize treatments for hereditary or acquired immunodeficiency disorders and related conditions?
What are the potential implications of the projected growth in the global plasma derived therapy market on healthcare accessibility and innovation?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Mar 2024
Coverage
biosp
pharm
prece
proth